Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study
- Herbert Y. Meltzer,
M.D. , - Josephine Cucchiaro,
Ph.D. , - Robert Silva,
Ph.D. , - Masaaki Ogasa,
M.S. , - Debra Phillips,
- Jane Xu,
Ph.D. , - Amir H. Kalali,
M.D. , - Edward Schweizer,
M.D. , - Andrei Pikalov,
M.D., Ph.D. , and - Antony Loebel,
M.D.
From the Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tenn.; Sunovion Pharmaceuticals, Inc., Fort Lee, N.J.; Kanazawa University, Ishikawa, Japan; Quintiles, Inc., San Diego; the Department of Psychiatry, University of California, San Diego; and the Paladin Consulting Group, Hoboken, N.J.
From the Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tenn.; Sunovion Pharmaceuticals, Inc., Fort Lee, N.J.; Kanazawa University, Ishikawa, Japan; Quintiles, Inc., San Diego; the Department of Psychiatry, University of California, San Diego; and the Paladin Consulting Group, Hoboken, N.J.
From the Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tenn.; Sunovion Pharmaceuticals, Inc., Fort Lee, N.J.; Kanazawa University, Ishikawa, Japan; Quintiles, Inc., San Diego; the Department of Psychiatry, University of California, San Diego; and the Paladin Consulting Group, Hoboken, N.J.
From the Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tenn.; Sunovion Pharmaceuticals, Inc., Fort Lee, N.J.; Kanazawa University, Ishikawa, Japan; Quintiles, Inc., San Diego; the Department of Psychiatry, University of California, San Diego; and the Paladin Consulting Group, Hoboken, N.J.
From the Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tenn.; Sunovion Pharmaceuticals, Inc., Fort Lee, N.J.; Kanazawa University, Ishikawa, Japan; Quintiles, Inc., San Diego; the Department of Psychiatry, University of California, San Diego; and the Paladin Consulting Group, Hoboken, N.J.
From the Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tenn.; Sunovion Pharmaceuticals, Inc., Fort Lee, N.J.; Kanazawa University, Ishikawa, Japan; Quintiles, Inc., San Diego; the Department of Psychiatry, University of California, San Diego; and the Paladin Consulting Group, Hoboken, N.J.
From the Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tenn.; Sunovion Pharmaceuticals, Inc., Fort Lee, N.J.; Kanazawa University, Ishikawa, Japan; Quintiles, Inc., San Diego; the Department of Psychiatry, University of California, San Diego; and the Paladin Consulting Group, Hoboken, N.J.
From the Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tenn.; Sunovion Pharmaceuticals, Inc., Fort Lee, N.J.; Kanazawa University, Ishikawa, Japan; Quintiles, Inc., San Diego; the Department of Psychiatry, University of California, San Diego; and the Paladin Consulting Group, Hoboken, N.J.
From the Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tenn.; Sunovion Pharmaceuticals, Inc., Fort Lee, N.J.; Kanazawa University, Ishikawa, Japan; Quintiles, Inc., San Diego; the Department of Psychiatry, University of California, San Diego; and the Paladin Consulting Group, Hoboken, N.J.
From the Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tenn.; Sunovion Pharmaceuticals, Inc., Fort Lee, N.J.; Kanazawa University, Ishikawa, Japan; Quintiles, Inc., San Diego; the Department of Psychiatry, University of California, San Diego; and the Paladin Consulting Group, Hoboken, N.J.
Supplemental Material
ajp_168_09_957_01.pdf (429 KB)